1. Home
  2. WALD vs SPRO Comparison

WALD vs SPRO Comparison

Compare WALD & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Waldencast plc

WALD

Waldencast plc

HOLD

Current Price

$1.66

Market Cap

187.3M

ML Signal

HOLD

Logo Spero Therapeutics Inc.

SPRO

Spero Therapeutics Inc.

HOLD

Current Price

$2.17

Market Cap

156.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WALD
SPRO
Founded
1988
2013
Country
United Kingdom
United States
Employees
364
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
187.3M
156.3M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
WALD
SPRO
Price
$1.66
$2.17
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$2.00
N/A
AVG Volume (30 Days)
664.0K
1.6M
Earning Date
03-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
111.81
EPS
N/A
N/A
Revenue
N/A
$66,802,000.00
Revenue This Year
$9.89
N/A
Revenue Next Year
$4.31
$300.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
39.24
52 Week Low
$0.72
$1.80
52 Week High
$3.22
$3.08

Technical Indicators

Market Signals
Indicator
WALD
SPRO
Relative Strength Index (RSI) 53.23 39.93
Support Level $1.47 $2.09
Resistance Level $1.95 $2.47
Average True Range (ATR) 0.14 0.21
MACD -0.01 -0.01
Stochastic Oscillator 55.00 19.55

Price Performance

Historical Comparison
WALD
SPRO

About WALD Waldencast plc

Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Share on Social Networks: